Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

NCT04610476 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Psoriatic Arthritis
Withdrawal
Reduction

Interventions

DRUG: Prednisolone
DRUG: Sulfasalazine
DRUG: Leflunomide
DRUG: Methotrexate
DRUG: Tofacitinib
DRUG: Apremilast
DRUG: Etanercept
DRUG: Adalimumab
DRUG: Infliximab
DRUG: Certolizumab pegol
DRUG: Golimumab
DRUG: Abatacept
DRUG: Secukinumab
DRUG: Ixekizumab
DRUG: Ustekinumab

Sponsor

University of Erlangen-Nürnberg Medical School